DUNHAM TRUST Co’s Design Therapeutics DSGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$96.4M Hold
7,668,710
– – 43.6% 1
2026
Q2
$111M Buy
+7,668,710
New +$95.6M 51.08% 1
2025
Q4
$71.9M Buy
+7,668,710
New +$60M 46.1% 1

Other funds holding DSGN

DUNHAM TRUST Co's DSGN Position: Q3 2026 in Review

DUNHAM TRUST Co held its Design Therapeutics (DSGN) position steady in Q3 2026 at 7,668,710 shares worth $96.4M. The position accounts for 43.6% of the portfolio, ranked #1.

DUNHAM TRUST Co first reported a position in DSGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $111M in Q2 2026. 140 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • DUNHAM TRUST Co held 7,668,710 shares of Design Therapeutics worth $96.4M as of Q3 2026.
  • DUNHAM TRUST Co left its Design Therapeutics share count unchanged in Q3 2026.
  • Design Therapeutics made up 43.6% of DUNHAM TRUST Co's portfolio in Q3 2026, its #1 holding.
  • DUNHAM TRUST Co first reported a position in Design Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • DUNHAM TRUST Co's Design Therapeutics position peaked at $111M in Q2 2026.
  • 140 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on DUNHAM TRUST Co's 13F filing for Q3 2026, filed 16 Nov 2026.